Nilotinib Zentiva (Nilotinib)

Nilotinib blocks the ATP‑binding site of the BCR‑ABL tyrosine kinase, preventing the enzyme from phosphorylating downstream proteins. This inhibition stops the signaling cascade that drives uncontrolled proliferation of leukemic cells, leading to reduced tumor burden and improved disease control.

The dose of Nilotinib Zentiva is individualized and set by the prescribing physician based on the patient’s disease phase, weight, liver function, and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of nilotinib in pregnancy or while breastfeeding has not been established. The drug is generally avoided in these situations unless the potential benefit outweighs the risk, and it should only be used under close medical supervision.

To request Nilotinib Zentiva, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL tyrosine kinase inhibitor, offering higher potency and activity against many imatinib‑resistant mutations. Compared with first‑generation agents like imatinib, nilotinib often achieves faster and deeper molecular responses, though both share similar safety considerations such as QT prolongation.

Nilotinib Zentiva should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct light, and avoid exposing them to excessive heat or humidity.

The medication is taken orally as a whole tablet, usually with a low‑fat meal to improve absorption. Patients should swallow the tablet with water and follow the timing schedule prescribed by their healthcare provider.

Key serious risks include QT interval prolongation that can lead to cardiac arrhythmias, significant liver enzyme elevations indicating hepatic injury, and severe neutropenia or thrombocytopenia that increase infection or bleeding risk. Prompt medical evaluation is needed if any of these occur.

Patients with known hypersensitivity to nilotinib or any of its excipients, those with uncontrolled cardiac conditions that predispose to QT prolongation, and individuals with severe hepatic impairment should avoid using Nilotinib Zentiva unless a specialist determines it is appropriate.